Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Other Accumulated Expenses (2016 - 2026)

Spyre Therapeutics' Other Accumulated Expenses history spans 11 years, with the latest figure at $179000.0 for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses fell 64.27% year-over-year to $179000.0; the TTM value through Dec 2025 reached $179000.0, down 64.27%, while the annual FY2025 figure was $179000.0, 64.27% down from the prior year.
  • Other Accumulated Expenses reached $179000.0 in Q4 2025 per SYRE's latest filing, up from $170000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $1.1 million in Q2 2021 to a low of $170000.0 in Q3 2025.
  • Average Other Accumulated Expenses over 5 years is $472111.1, with a median of $378500.0 recorded in 2023.
  • Peak YoY movement for Other Accumulated Expenses: surged 97.82% in 2022, then plummeted 67.68% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $783000.0 in 2021, then tumbled by 57.85% to $330000.0 in 2022, then soared by 47.88% to $488000.0 in 2023, then grew by 2.66% to $501000.0 in 2024, then plummeted by 64.27% to $179000.0 in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Other Accumulated Expenses are $179000.0 (Q4 2025), $170000.0 (Q3 2025), and $242000.0 (Q2 2025).